Why Rare Disease Research Is Driving Innovation Across Clinical Development

TL;DR

Rare diseases have challenged researchers to rethink how clinical trials are designed, therapies are developed, and patient outcomes are measured. The innovations born from these challenges—from precision medicine and gene therapies to patient-centered trials and real-world evidence—are now reshaping drug development far beyond rare diseases.

Rare vs. General Indications

The difficulties of conducting a clinical trial are often amplified in rare diseases. Numerous factors can create delays and substantial barriers throughout the process. Many of you may be familiar with the common obstacles and bottlenecks associated with rare disease trials. Yet, it is precisely these challenges that drive clinical researchers and trial teams to develop unique solutions, innovative technologies, and new perspectives that challenge the often formulaic approach to clinical trial design.

It is important to note that rare diseases are defined by their low prevalence within a population, not by the rarity of their underlying disease mechanisms. In fact, many rare diseases have clearly identifiable biological causes. This contrasts with many more common diseases, such as asthma, hypertension, and type 2 diabetes, where multiple genetic, environmental, and lifestyle factors may each contribute small effects that collectively lead to disease. While many rare diseases also involve complex interactions between biological and environmental factors, a substantial number are driven by specific genetic or molecular abnormalities that provide clear targets for intervention. These diseases have proven particularly valuable for advancing personalized therapies, informing supportive regulatory frameworks, and enabling innovative approaches to data modeling and clinical trial prediction.

Innovations in Clinical Research

There have been clear ways that investigating rare diseases have influenced the current clinical development pipeline. The following points highlight some tools and changes that sprouted from rare disease research and are now incorporated widely among complex clinical trials.

Tailored Drug Discovery
- The use of phenotyping—systematically characterizing a person’s observable traits, symptoms, and disease features in combination with genomic diagnosis, which identifies disease-causing changes in a person’s DNA, has transformed the development of precision therapies. Together, these approaches provide a more complete picture of both how a disease presents and why it occurs, enabling the creation of target product profiles that serve as blueprints for the ideal therapy. They also identify which genotypes (an individual’s unique genetic makeup) are most likely to respond to a treatment and help prioritize the most informative biomarkers, measurable biological indicators, that act like the body’s dashboard lights by revealing disease activity and treatment response. Collectively, these advances allow researchers to design therapies more strategically, match them to the patients most likely to benefit, and evaluate their effectiveness with greater precision.
Improved Translation Models
- Animal models have long served as the cornerstone for evaluating new therapies before they enter human clinical trials. However, rare disease research has highlighted their limitations, as many animal models do not fully replicate the biology of human disease or reliably predict therapeutic safety and efficacy. Emerging translational models—including organoids (miniature, lab-grown versions of human organs), disease-specific assays (specialized laboratory tests that measure how a disease functions at the cellular level), and patient-derived cells (cells grown from an individual’s own tissue)—provide more human-relevant systems for studying disease. These models help researchers interpret the biological impact of genetic variants, identify patients most likely to benefit from a therapy, and generate evidence to support treatment decisions, particularly when a disease-causing mutation is too rare for evaluation in a traditional clinical trial.
Incorporating Natural History Evidence
- When patient populations are small, studying natural history—how a disease develops and progresses without an experimental treatment—provides critical insights that can guide therapy development. By analyzing data from patient registries (organized collections of health information), electronic health records (medical records collected during routine clinical care), and observational studies (research that follows patients without assigning an intervention), researchers can better understand when a disease begins, how it changes over time, and how different genotypes (genetic variants) influence observable disease features, or phenotypes. These data help identify the optimal window for intervention, uncover prognostic factors (characteristics that predict how a disease is likely to progress), and determine meaningful clinical endpoints (measurable outcomes that demonstrate whether a treatment is effective). Because these insights are especially valuable when traditional clinical trials are difficult to conduct, the FDA recognizes well-designed natural history studies as an important source of evidence in rare disease drug development.
Patient-Focused Endpoints and Decentralized Measurements
- To ensure clinical trials measure outcomes that truly matter, the patient lived experience—how a disease affects daily life, independence, and quality of life—should help shape the selection of clinical endpoints (the measurable outcomes used to determine whether a treatment is effective). This patient-centered approach has driven the development of innovative digital health technologies, including wearable devices and remote monitoring tools, that capture meaningful health data while reducing the burden of frequent clinic visits for patients and caregivers. By enabling assessments to be completed closer to home, these technologies can improve participation among geographically dispersed patients, increase retention in clinical trials, and generate results that better reflect real-world use. Recognizing the importance of patient-centered measurement, the Rare Disease Clinical Outcome Assessment (COA) Consortium was established to develop scientifically rigorous tools that capture outcomes most meaningful to people living with rare diseases. These tools are also being used more actively across indications.
Earlier Regulatory Interactions
- Early engagement with regulatory agencies—organizations such as the FDA that evaluate the safety and effectiveness of new therapies—helps transform scientific uncertainty into a clear, shared plan for generating the evidence needed for approval before costly late-stage clinical trials begin. For rare diseases, this process is supported by expedited development programs (pathways designed to speed the development and review of promising therapies), orphan drug incentives (regulatory and financial benefits that encourage treatments for rare conditions), and disease-specific regulatory guidance that addresses the unique challenges of small patient populations. The FDA’s rare disease guidance spans topics including natural history studies, biomarkers, clinical outcome assessments (COAs), external control groups, innovative and decentralized trial designs, master protocols, individualized antisense oligonucleotide (ASO) therapies, and real-world evidence, providing a framework for designing studies that are both scientifically rigorous and feasible for rare disease research.
Long Term Therapeutic Evidence
- The impact of a therapy extends well beyond its initial approval, making long-term follow-up essential to understanding its full benefits and risks. By using patient registries (organized collections of health information) and real-world data (health information collected during routine clinical care rather than in a clinical trial), researchers can monitor how long treatment benefits last, identify side effects that emerge over time, evaluate treatment effectiveness in everyday clinical practice, and understand barriers to patient access. This ongoing evidence generation is particularly important for irreversible or long-acting therapies, such as gene and cell therapies, where treatment effects cannot easily be reversed or repeated. Together, these data support life-cycle benefit–risk management—the continuous evaluation of a therapy’s safety and effectiveness throughout its lifespan—and help guide its safe and effective use in routine clinical care after approval.

Landmark Clinical Research Breakthroughs

Molecularly Matched Treatments
- Cystic Fibrosis (CF) transformed the treatment of genetic disease by demonstrating that therapies can be designed to correct the underlying molecular defect rather than simply manage its symptoms. CFTR modulators are medicines that improve the function of the defective CFTR protein, with different drugs targeting specific classes of CFTR gene variants based on how they disrupt protein function. This precision approach has significantly improved outcomes for many people with CF while establishing a new model for genotype-guided therapy—matching treatment to a patient’s specific genetic variant. For individuals with rare CFTR variants, patient-derived organoids (miniature, lab-grown versions of a patient’s tissues) can be used to test whether a therapy is likely to be effective before treatment begins. Together, these advances have provided a blueprint for mechanism-based precision medicine, influencing drug development across inherited diseases, oncology, and pharmacogenomics by demonstrating how an understanding of disease biology can guide more personalized and effective treatments.
RNA Therapeutics
- RNA-targeted therapies—treatments that modify how genetic information is processed rather than altering the DNA itself—including splice modulation (changing how RNA is assembled into its final form), exon skipping (selectively excluding sections of RNA to restore protein function), and, in some cases, individualized antisense oligonucleotide (ASO) therapies were designed for a single patient’s genetic variant. A landmark example is Spinal Muscular Atrophy (SMA), where nusinersen is an ASO that binds to the SMN2 pre-mRNA and promotes inclusion of exon 7 during RNA splicing. This increases production of full-length, functional survival motor neuron (SMN) protein, partially compensating for the loss of the SMN1 gene and improving motor function in people with SMA.
Systemic In-Vivo Gene Replacement
- SMA also marked a major milestone in the development of gene therapy—a treatment approach that delivers a functional copy of a gene to address the underlying cause of disease. Onasemnogene abeparvovec (Zolgensma) uses an adeno-associated virus (AAV) vector, a modified virus that serves as a delivery vehicle, to transport a working copy of the SMN1 gene into motor neurons. As a one-time treatment, it demonstrated that gene replacement could dramatically alter the course of a severe, life-threatening childhood disease. In clinical studies, infants treated with Zolgensma achieved improved survival and key motor milestones, such as sitting independently, at rates that exceeded what had been observed in the natural history of untreated infantile-onset SMA. Beyond its impact on patients, this work advanced the broader field of gene therapy by informing vector engineering, pediatric clinical development, immune monitoring, dose selection, and the long-term safety surveillance needed for durable genetic medicines.
Durable Protein Production Through Gene Transfer
- Hemophilia B provided another landmark example of how gene therapy can replace a missing protein with a single treatment. Etranacogene dezaparvovec (HEMGENIX) uses an AAV vector to introduce a highly active version of the Factor IX gene, known as the Padua variant, into liver cells. Once delivered, the liver produces Factor IX, the blood-clotting protein that people with Hemophilia B lack or produce in insufficient amounts. In the pivotal clinical trial, this one-time infusion substantially reduced annual bleeding episodes and decreased the need for routine Factor IX replacement therapy, demonstrating that sustained production of a therapeutic protein could be achieved through gene transfer. Beyond its clinical success, HEMGENIX helped establish important approaches for monitoring transgene expression (how effectively the introduced gene produces its intended protein), evaluating immune responses to AAV vectors, comparing outcomes before and after treatment within the same patient, and conducting the long-term safety surveillance needed for gene therapies.

Looking Ahead

In summary, rare disease research is often defined by its challenges. Yet these very obstacles have become catalysts for some of the most meaningful innovations in clinical development. From precision diagnostics and human-relevant models to patient-centered endpoints, adaptive trial strategies, and transformative genetic medicines, rare disease research has driven new approaches to overcoming barriers that once seemed insurmountable. While many of these advances were developed out of necessity for rare conditions, their impact extends far beyond rare disease—reshaping how all clinical trials are designed, conducted, and evaluated. Ultimately, progress in clinical research is built through the collective efforts of scientists, clinicians, patients, regulators, and advocates. Each contribution, whether large or small, helps move us closer to a future where developing better, more meaningful therapies is not the exception, but the standard.